Evidence map›Paper›PMID 42041976›Full record

ReviewJournal of cardiovascular development and disease2026

State-of-the-Art Definitive Femoropopliteal Lesion Treatment: A Case-Based Systematic Approach.

Grigorios Korosoglou, Nasser Malyar, Andrej Schmidt, Michael Lichtenberg, Gerd Grözinger, Dittmar Böckler, Christian A Behrendt, Erwin Blessing, Ralf Langhoff, Thomas Zeller and 1 more

Abstract readReview
In one paragraph

Review in Journal of cardiovascular development and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Grigorios KorosoglouGRN Hospital Weinheim, Cardiology and Vascular Medicine, 69469 Weinheim, Germany.ORCID 0000-0002-6038-2253
Nasser MalyarDepartment of Cardiology I-Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Muenster, 48149 Muenster, Germany.ORCID 0000-0001-9912-2814
Andrej SchmidtDivision of Angiology, University Hospital Leipzig, 04103 Leipzig, Germany.
Michael LichtenbergVascular Center, Klinikum Arnsberg, 59821 Arnsberg, Germany.
Gerd GrözingerDepartment of Radiology, SLK-Kliniken Heilbronn GmbH, 74078 Heilbronn, Germany.
Dittmar BöcklerDepartment of Vascular and Endovascular Surgery, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Christian A BehrendtDepartment of Vascular and Endovascular Surgery, Asklepios Clinic Wandsbek, Asklepios Medical School, 22043 Hamburg, Germany.ORCID 0000-0003-0406-3319
Erwin BlessingUniversity Heart and Vascular Center, Department of Angiology, University Hospital Hamburg-Eppendorf, 20246 Hamburg, Germany.ORCID 0000-0003-0205-9084
Ralf LanghoffDepartment of Angiology, Center for Internal Medicine I, Campus Clinic Brandenburg, Brandenburg Medical School Theodor Fontane, 14770 Brandenburg an der Havel, Germany.ORCID 0000-0003-0455-5081
Thomas ZellerDepartment of Interventional Angiology, University Hospital Freiburg/Bad Krozingen, 79189 Bad Krozingen, Germany.ORCID 0000-0003-2704-3871
Christos RammosDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University of Duisburg-Essen, 45141 Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

After vessel preparation, using different strategies such as balloon angioplasty, specialty balloons, atherectomy or intravascular lithotripsy, definitive treatment has emerged as a key feature in endovascular treatment strategies. Based on current guidelines, endovascular treatment is the most common treatment option in patients with claudication. In patients with chronic limb-threatening ischemia (CLTI), on the other hand, the best treatment modality, including bypass surgery and endovascular revascularization, needs to be selected by an interdisciplinary team, focusing on individual anatomic and patient-specific characteristics, on the availability of a vein graft and on cardiovascular and other comorbidities of the patients. With endovascular therapy, currently, a plethora of options are available for the treatment of femoropopliteal lesions, which are increasingly gaining in complexity. Therefore, a practical systematic case-based approach, entailing contemporary treatment options, like drug-coated balloon (DCB) angioplasty tools, self-expanding bare-metal stents (BMSs), drug-eluting stents (DESs), interwoven stents and covered stents, is crucial. Generally, most endovascular operators adhere to the 'leave nothing behind' concept, meaning that, after proper lesion preparation, lesions can be treated with DCBs, avoiding the implantation of permanent metallic implants. However, in the case of severe dissections or significant recoil, stent implantation becomes necessary to achieve adequate limb perfusion. The selection between long versus spot stenting and the different stent options depends on the current scientific evidence, guidelines and expert opinion statements. An interdisciplinary expert consensus was recently compiled on how these modalities should be used in specific lesions and patients in the femoropopliteal segment. Herein we present a practical case-based approach, which is based on this algorithm and aims at harmonization of endovascular treatment strategies in daily practice and ultimately at further improvements in limb and patient outcomes.

Indexed as

bare-metal stents (BMSs)case-based approachchronic total occlusions (CTOs)definitive lesion treatmentdrug-coated balloon angioplasty (DCB)drug eluting stents (DESs)femoropopliteal lesionsinterwoven stents

Identifiers

PMID42041976
PMCPMC13115987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.